ribosomal protein L36a likeGenealiases: RPL36A · RPL36AP42 · RPL36A_18_1363
Q-omics provides the consensus-scored RPL36AL profile across patient tissues and cancer cell-line models. RPL36AL expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL36AL is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RPL36AL RNA expression shows 18,005 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where RPL36AL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AL survival associations across molecular data types. RPL36AL RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AL RNA expression–survival associations across cancer types. High RPL36AL expression shows unfavorable associations in HNSC, KICH, ACC, UCS and LUAD, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL36AL RNA expression.
This table summarizes RPL36AL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL36AL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AL shows lower tumor expression in UCEC and LUSC and higher tumor expression in KIRC, LIHC, CHOL and ESCA. The KIRC box plot shows higher RPL36AL RNA expression in tumor versus normal tissue (log2 FC = +0.517, t-test p < 0.001).
This table shows molecular features associated with RPL36AL in patient tissues and cancer cell lines. In patient samples, RPL36AL shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL36AL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
